Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2010 Jul 13;103(4):581–589. doi: 10.1038/sj.bjc.6605776

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2010 Cancer Research UK

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Genetic-based algorithm for first-line treatment selection in colorectal cancer patients. An X in a genotype represents any of the possible alleles. A given patient would be first genotyped for TYMS. If he were heterozygous or homozygous for the 3TRP allele, he would receive an oxaliplatin-based regimen. If he was not, he would be then genotyped for UGT1A1^*28. If genotype was UGT1A1^*28/^*28, this patient would receive a low dose of irinotecan, otherwise he would be genotyped for UGT1A7^*3. If he were homozygous for the UGT1A7^*3 allele, he would receive a low dose of irinotecan. Genotypes different from UGT1A7^*3/^*3 would be then analysed for UGT1A9^*22. If the resulting genotype was UGT1A9^*1/^*1, this patient would receive a low dose of irinotecan, otherwise he would receive a standard irinotecan plus 5FU schedule.